Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive share transactions rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of Emma Walmsley, a Person Discharging Managerial Responsibilities. On April 29, 2016, she exercised nil cost options over 14,789 and 5,583 Ordinary Shares granted on February 28, 2013, which vested on February 28, 2016, under the GlaxoSmithKline Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the mechanics of the share exercise and delivery.
Important Facts for Investors
- Executive Transaction: Emma Walmsley exercised options totaling 20,372 Ordinary Shares.
- Share Delivery: The Company delivered a net of tax value in shares amounting to 10,605 Ordinary Shares.
- Valuation: The fair market value of an Ordinary Share at the points of exercise was £14.78 and £14.79 respectively.
- Notification Date: The Company and Ms. Walmsley were advised of these transactions on May 3, 2016.